CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Trifericdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03303144
NCT03303144Phase 2Completed
CompareCT.gov

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Rockwell Medical Technologies, Inc.·interventional·Posted Oct 5, 2017·Updated Nov 16, 2020

In Brief

A Phase 2 clinical trial evaluating Triferic for End Stage Renal Disease. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The main purpose is to establish the equivalence of Triferic iron administered via dialysate into the arterial blood line and into the venous blood line

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 5, 2017
Enrollment StartOct 1, 2017
Primary CompletionDec 28, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.7 years ago

Interventions

Trifericdrug

ferric pyrophosphate citrate